[go: up one dir, main page]

WO2019026930A1 - Composition alimentaire pour augmenter la masse musculaire, agent d'augmentation de masse musculaire, agent thérapeutique pour le syndrome de la locomotion, agent thérapeutique pour la sarcopénie, agent d'entretien de fonction d'exercice, inhibiteur d'expression génique liée à une atrophie musculaire, inhibiteur de dégradation de protéine musculaire, agent de prévention d'atrophie musculaire, promoteur d'expression génique liée à la synthèse musculaire, et promoteur de synthèse musculaire - Google Patents

Composition alimentaire pour augmenter la masse musculaire, agent d'augmentation de masse musculaire, agent thérapeutique pour le syndrome de la locomotion, agent thérapeutique pour la sarcopénie, agent d'entretien de fonction d'exercice, inhibiteur d'expression génique liée à une atrophie musculaire, inhibiteur de dégradation de protéine musculaire, agent de prévention d'atrophie musculaire, promoteur d'expression génique liée à la synthèse musculaire, et promoteur de synthèse musculaire Download PDF

Info

Publication number
WO2019026930A1
WO2019026930A1 PCT/JP2018/028756 JP2018028756W WO2019026930A1 WO 2019026930 A1 WO2019026930 A1 WO 2019026930A1 JP 2018028756 W JP2018028756 W JP 2018028756W WO 2019026930 A1 WO2019026930 A1 WO 2019026930A1
Authority
WO
WIPO (PCT)
Prior art keywords
muscle
euglena
agent
related gene
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2018/028756
Other languages
English (en)
Japanese (ja)
Inventor
綾香 中島
鈴木　健吾
立花　宏文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyushu University NUC
Euglena Co Ltd
Original Assignee
Kyushu University NUC
Euglena Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2017254319A external-priority patent/JP6524204B2/ja
Application filed by Kyushu University NUC, Euglena Co Ltd filed Critical Kyushu University NUC
Priority to CN201880049823.XA priority Critical patent/CN111031812A/zh
Publication of WO2019026930A1 publication Critical patent/WO2019026930A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Definitions

  • the present invention provides a food composition for increasing muscle mass, an agent for increasing muscle mass, an agent for treating locomotive syndrome, an agent for treating sarcopenia and a maintenance agent for motor function, an agent for suppressing muscle atrophy-related gene expression, an agent for suppressing muscle protein degradation, an agent for preventing muscle atrophy
  • the present invention relates to a muscle synthesis related gene expression promoter and a muscle synthesis promoter.
  • Non-Patent Document 1 According to the Japanese Orthopedic Association, locomotive syndrome is a disorder in one or more of bone, joints, cartilage, intervertebral disc, muscles such as intervertebral disc, muscles, and functions such as "stand up” or "walk” are reduced. It is defined that it is a state (nonpatent literature 2).
  • Sarcopenia refers to muscle weakness associated with loss of muscle mass due to aging, illness, lack of exercise, malnutrition, etc., and decrease in physical function
  • locomotive syndrome refers to exercise of muscles, bones, etc. due to aging or lack of exercise It points to the state where troubles occurred in the part of the vessel and daily life became difficult.
  • locomotive syndrome is a concept that includes general motor symptoms
  • sarcopenia can be said to be a symptom that focuses on muscle mass, muscle strength, and physical function among the motor organs.
  • Euglena (genus: Euglena, Japanese name: Midorimusi) is attracting attention as a biological resource which is considered to be promising for food, feed, fuel and the like.
  • Euglena is a supplement for the well-balanced intake of many types of nutrients, with 59 types of nutrients corresponding to most of the nutrients necessary for human beings to live including vitamins, minerals, amino acids, unsaturated fatty acids, etc. It has been suggested that it could be used as a food source in poor areas where it can not consume necessary nutrients.
  • Euglena is a primary producer of the food chain, and it is a large-scale culture because it is difficult to prey on predators and culture conditions such as light, temperature conditions, and agitation speed are higher than other microorganisms.
  • our extensive research has established a large-scale culture technique and opened the way to large-scale supply of Euglena-derived substances such as Euglena and Paramylon extracted from Euglena.
  • Euglena is a unique organism that has the property of carrying out flagellum movement and at the same time carries out photosynthesis with chloroplast as a plant, and it is expected that Euglena itself and substances derived from Euglena have many functions. ing. Therefore, it is desirable to develop a method of using Euglena and Euglena-derived substances that can be supplied in large quantities.
  • the present invention has been made in view of the above problems, and the object of the present invention is to be able to be taken continuously continuously, to effectively increase muscle mass, to treat locomotive syndrome and sarcopenia, Food composition for increasing muscle mass that can be prevented and improved, muscle mass increasing agent, locomotive syndrome therapeutic agent, sarcopenia therapeutic agent, motor function maintenance agent, muscle atrophy related gene expression inhibitor, muscle protein degradation inhibitor, An object of the present invention is to provide a muscle atrophy preventive agent, a muscle synthesis related gene expression promoter and a muscle synthesis promoter.
  • the present inventors have an effect of increasing muscle mass in Euglena, an action of suppressing muscle atrophy, an action of suppressing degradation of muscle proteins, and an action of promoting muscle synthesis.
  • the present invention has been completed.
  • the above-mentioned subject is solved by the food composition for increasing muscle mass characterized by containing an Euglena-derived substance as an active ingredient.
  • the Euglena-derived substance is preferably Euglena.
  • it may be a muscle mass increasing food composition used to increase the amount of quadriceps.
  • the above-mentioned problems are solved by a muscle mass increasing agent characterized by containing an Euglena-derived substance as an active ingredient.
  • a food composition containing an Euglena-derived substance as an active ingredient for sarcopenia prevention, sarcopenia improvement, locomotive syndrome prevention or locomotive syndrome improvement.
  • a locomotive syndrome preventive agent, a locomotive syndrome therapeutic agent, a sarcopenia preventive agent, a sarcopenia therapeutic agent, a motor function maintenance agent exercise comprising the euglena-derived substance as an active ingredient. It is solved by the function improving agent.
  • the subject contains an Euglena-derived substance as an active ingredient, and is for suppressing muscle atrophy-related gene expression, for suppressing muscle protein degradation, for preventing muscle atrophy, for promoting muscle synthesis-related gene expression or It is solved by a food composition for promoting synthesis.
  • a muscle atrophy-related gene expression inhibitor characterized by containing an Euglena-derived substance as an active ingredient, a muscle protein degradation inhibitor, a muscle atrophy preventive agent, a muscle synthesis related gene expression It is solved by the promoter and the muscle synthesis promoter.
  • the agent for preventing atrophy, muscle synthesis related gene expression promoter and muscle synthesis promoter can be provided.
  • the synthetic related gene expression promoter and muscle synthesis promoter have no reports of adverse effects and have Euglena as the active ingredient with a level of safety that conforms to the Food Sanitation Law. It can be taken.
  • Experiment 1 it is a graph which shows a body weight change when each test meal is continuously fed for 4 weeks.
  • 6 is a graph showing the amount of food consumed by the test food in Test 1. It is a graph which shows the liver weight at the end of test 1. It is a graph which shows quadriceps femoris muscle weight at the end of test 1 (Tukey's test, * p ⁇ 0.05 vs. control group).
  • a muscle mass increasing food composition containing an Euglena-derived substance as an active ingredient, a muscle mass increasing agent, a locomotive syndrome therapeutic agent, a sarcopenia therapeutic agent, a motor function maintenance agent, a muscle atrophy-related gene expression inhibitor, a muscle
  • the present invention relates to a protein degradation inhibitor, a muscle atrophy preventive agent, a muscle synthesis related gene expression promoter and a muscle synthesis promoter.
  • locomotive syndrome (locomotive syndrome) is characterized by the ability to “stand up” or “walk” due to injury to one or more of bone, joint, cartilage, intervertebral disc, muscle, or muscle It is defined as being in a state of decline (Non-Patent Document 2).
  • Locomotive syndrome may be abbreviated as Locomo, or may be called locomotive syndrome, motor organ syndrome or the like.
  • diagnostic criteria for locomotive syndrome will be described (Noriko Yoshimura, “Clinical diagnostic value and prevalence of locomotive syndrome", Japanese Geriatrics Journal 52, 4 350-353 (2015)).
  • the locomotion test which is one of diagnostic criteria for locomotive syndrome, comprises (1) rising test, (2) two-step test, and (3) locomo 25.
  • Stand-up test is a test of measuring the leg strength based on whether one leg or both legs can stand up by preparing a stand of four heights of 10 cm, 20 cm, 30 cm and 40 cm.
  • Second In the two-step test walk two steps with as much as possible, measure the stride for two steps, and divide by the height to calculate a two-step value. Evaluate walking ability including leg strength, balance ability, flexibility etc. of lower limbs by 2-step value.
  • Locomo 25 evaluates with a 25-item questionnaire about whether or not there was body pain or difficulty in daily life in the past one month.
  • locomotion degree 1 The clinical judgment value of locomotion degree 1 is as follows. 1) Rise test: Can not get up from a height of 40 cm with either one leg 2) 2 step test: 2 step value less than 1.3 3) Locomo 25: Locomo 25 result is 7 points or more Above 1)- If any one of the above 3) applies, it is determined as "Locomor 1", and it is determined that the mobile function has started to deteriorate.
  • locomotion degree 2 The clinical judgment value of locomotion degree 2 is as follows. 1) Rise test: Can not stand from height of 20 cm with both legs 2) 2 step test: 2 step value less than 1.1 3) Locomo 25: Locomo 25 result is 16 points or more Any of the above 1) to 3) If any one of the cases is true, it is judged as "Locomor 2", and it is judged that the deterioration of the mobile function is progressing.
  • Sarcopenia is a syndrome characterized by atrophy of skeletal muscle with age, accompanied by loss of skeletal muscle mass and muscle strength or loss of physical function.
  • sarcopenia many diagnostic criteria that differ depending on the country, region, etc. have been proposed, but it is considered as a sarcopenia when muscle loss is an essential item, and it falls under either muscle strength or physical ability "Sarcopenia's diagnosis, pathophysiology and treatment" Journal of Japan Geriatrics Journal Vol. 52, No. 4, 343-349 (2015)).
  • the limb skeletal muscle mass is the muscle mass of the limb divided by the height (m) squared
  • DXA dual energy X-ray absorptiometry
  • the walking speed of 10m is less than 0.8 m / sec, or grip strength in men Sarcopenia is diagnosed if it is less than 30 kg and less than 20 kg in women.
  • the procedure of diagnosis is to measure the walking speed first and measure limb skeletal muscle mass if it is less than 0.8 m / s, and it is 7.23 kg / m 2 or less for men and 5.67 kg / m for women. If it is m 2 or less, sarcopenia is diagnosed. If it is high, it is not diagnosed as sarcopenia. If walking speed is faster than 0.8 m / sec, grip strength is measured and if it is higher than 30 kg for males and 20 kg for females it is not diagnosed as sarcopenia, if it is higher, limb skeletal muscle mass is measured Sarcopenia if below the diagnostic threshold, not sarcopenia if above the diagnostic threshold.
  • the diagnostic criteria of the EWGSOP are the criteria developed by the working group in Europe, and because there is a difference in physique and physical function between Europeans and Asians, the working group for sarcopenia in Asia, ASIAN working Group FOR SARCPOPENIA (AWGS) Has established diagnostic criteria for Asians.
  • the AWGS diagnostic criteria differ from the EWGSOP diagnostic criteria and the criteria for grip strength and muscle mass.
  • the standard of grip strength diagnosed with sarcopenia is less than 26 kg for men and less than 18 kg for women, and the criteria for muscle mass are 7 kg / m 2 or less for men (DXA value, BIA value), 5.4 kg for women 2 or less (DXA value), 5.7 kg / m 2 or less (BIA value).
  • the diagnostic criteria in the EWGSOP are based on the elderly of Western Americans, and Japanese and European Americans have differences in physique and lifestyle even with the elderly, so the simplified criteria of sarcopenia suitable for the elderly of Japanese A draft has been prepared by the National Longevity Medical Research Center Long-Term Longitudinal Epidemiological Study on Aging (NILS-LSA).
  • BMI values body mass index, height
  • a diagnosis of sarcopenia is made if the ratio of body weight to the square is an index representing body size) less than 18.5, or the lower leg circumference is less than 30 cm.
  • Normal when walking speed and grip strength are above standard values. Even if the walking speed and grip strength are below the standard value, BMI and lower leg circumference are above the standard value, it is diagnosed as a vulnerable elderly person but not sarcopenia.
  • Euglena includes all microorganisms classified into Euglena (Euglena) according to the zoological and botanical classification, variants thereof, and variants thereof.
  • the microorganisms of Euglena (Euglena) are, in zoology, the protozoan (Protozoa) dinoflagellate (Mastigophorea), and the Euglenoidina (Euglenida) belonging to the plant dinoflagellate (Phytomastigophorea) It is a microorganism belonging to the eye (Euglenoidina).
  • microorganisms of the genus Euglena belong to the order Euglenales belonging to the family Euglenophyceae of the family Agromorpha (Euglenophyta) in botany.
  • Euglena gracilis E. gracilis
  • E. gracilis E. gracilis
  • E. gracilis Z strain E. gracilis (E. gracilis) NIES-49 strain, etc.
  • Euglena ⁇ Mutant strain SM-ZK of E. gracilis Z strain chloroplast-deficient strain
  • Bacillaris, ⁇ -1 derived from gene mutant strains such as chloroplast mutant strains of these species , 3-glucanase, Euglena intermedia, Euglena piride, and other Euglenas, such as Astaia longa.
  • the genus Euglena is widely distributed in fresh water such as ponds and marshes, and may be used separately from them, or any Euglena isolated previously may be used.
  • the genus Euglena includes all its variants. Further, among these mutant strains, those obtained by genetic methods such as recombination, transduction, transformation and the like are also contained.
  • a culture solution for example, a culture solution to which nutrients such as nitrogen source, phosphorus source, and minerals have been added, for example, modified Cramer-Myers medium ((NH 4 ) 2 HPO 4 1.0 g / L , KH 2 PO 4 1.0 g / L, MgSO 4 ⁇ 7 H 2 O 0.2 g / l, CaCl 2 ⁇ 2 H 2 O 0.02 g / l, Fe 2 (SO 2 ) 3 ⁇ 7 H 2 O 3 mg / l, MnCl 2 ⁇ 4 H 2 O 1.8 mg / l, CoSO 4 ⁇ 7 H 2 O 1.5 mg / l, ZnSO 4 ⁇ 7 H 2 O 0.4 mg / l, Na 2 MoO 4 ⁇ 2 H 2 O 0.2 mg / l, CuSO 4 ⁇ 5H 2 O 0.02g / l, thiamine hydrochloride (vitamin B1) 0.1mg / l, thiamine hydrochloride (vitamin B1)
  • (NH 4 ) 2 HPO 4 can also be converted to (NH 4 ) 2 SO 4 or NH 3 aq.
  • well-known Hutner's medium and Koren-Hutner's medium prepared based on the description of Euglena Physiology and Biochemistry (Kitaoka Shozaburo, ed., Inc. publication center) may be used.
  • the pH of the culture solution is preferably 2 or more, and the upper limit thereof is preferably 6 or less, more preferably 4.5 or less.
  • photosynthetic microorganisms can be more preferentially grown than other microorganisms, so that contamination can be suppressed.
  • the culture of Euglena cells may be performed by an open pond method using sunlight directly, a method of sending sunlight collected by a light collecting device by an optical fiber or the like and irradiating it in a culture tank and utilizing it for photosynthesis.
  • culture of Euglena cells may be performed using, for example, a fed-batch method, but culture using a flask culture or a fermenter, batch culture method, half-batch culture method (feed-batch culture method), continuous culture method (perfusion It may be carried out by any liquid culture method such as culture method).
  • the separation of Euglena cells is performed, for example, by centrifugation, filtration or simple sedimentation of the culture fluid.
  • Euglena live cells separated by centrifugation, filtration, sedimentation or the like can be used as Euglena algal cells as they are.
  • Euglena living cells can be used as they are after harvesting from a culture tank, but washing with water or saline is preferred. Also, it may be used in the form of a dispersion in which Euglena algal cells are dispersed in a liquid such as water.
  • a mechanically treated product of algal cells obtained by performing ultrasonic irradiation treatment or mechanical treatment such as homogenization may be used as the euglena algal cells.
  • “Euglena aqueous solvent extract” means an extract extracted from Euglena using an aqueous solvent, and in particular, using water as an aqueous solvent, several seconds to several seconds at 5 ° C. to 600 ° C. It is preferred to use a water extract or a hot water extract of Euglena extracted for 10 hours.
  • the water used for the extraction does not necessarily have to be distilled water, pure water, or ultrapure water, and may be, for example, tap water or an impurity, but contains a component that hinders the extraction of the active ingredient. No water is preferred.
  • water extract means an extract with water of 0 to 50 ° C. (excluding 0 ° C.).
  • water means water of 0 to 50 ° C. (excluding 0 ° C.).
  • the temperature of water is not particularly limited as long as the active ingredient can be sufficiently extracted without affecting the active ingredient, but preferably 1 to 40 ° C., more preferably 5 to 35 ° C. Particularly preferred is 10 to 30 ° C.
  • hot water extract means an extract with water at a temperature higher than 50 ° C., and can also be called “hot water extract”.
  • hot water means water having a temperature higher than 50 ° C., and is a concept including “hot water”, including water in a boiling state. Further, it is not limited to hot water in a liquid state, and includes hot water in a gaseous state and in a supercritical state.
  • the temperature of the hot water is not particularly limited as long as the active ingredient can be sufficiently extracted without affecting the active ingredient, but is preferably higher than 50 ° C. and 120 ° C. or less, more preferably 50 It is higher than ° C and not higher than 100 ° C.
  • the pH of water used for extraction is not particularly limited as long as the active ingredient can be extracted sufficiently without affecting the active ingredient, but the pH is preferably 4 to 10, more preferably 5 to 9 The pH is particularly preferably 6 to 8.
  • water is used alone as the aqueous solvent, but the active ingredient can be sufficiently extracted without affecting the active ingredient, and one solvent can be generally used for extraction. Or you may select and use 2 or more types.
  • water, alcohol, glycols etc. can be mentioned, it is not limited to this.
  • alcohols include ethanol, methanol, n-propanol and isopropanol.
  • glycols include butylene glycol and propylene glycol.
  • Other aqueous solvents include acetone and the like. These solvents may be used alone or as an aqueous solution, and may be used as any two or more mixed solvents.
  • the temperature of the aqueous solvent used for extraction is, for example, 0 ° C. or higher, and is not particularly limited as long as it does not affect the active ingredient.
  • an aqueous solvent in a boiling or supercritical state can be used, it is preferable to use an aqueous solvent at 5 ° C. to 600 ° C., and it is more preferable to use an aqueous solvent at 10 ° C. to 200 ° C. Therefore, the aqueous solvent for extraction also includes an aqueous solvent in a boiling state or a supercritical state.
  • the amount of aqueous solvent used for extraction is preferably an amount capable of sufficiently dissolving the water-soluble active ingredient contained in Euglena.
  • the extraction method is also not particularly limited, and, for example, the extraction can be performed by the method described below, but it is not limited thereto, and a common extraction method can be freely selected and used.
  • Euglena water extraction can be carried out by the usual method as shown below, but is not limited thereto.
  • Euglena tissue and water are placed in a container and allowed to stand for a predetermined time while stirring or shaking as appropriate, and the obtained extract can be used as it is as a water extract.
  • the supernatant obtained by centrifuging such extract can be used as a water extract.
  • such extract or supernatant may be concentrated, dried to remove water and used as a water extract.
  • the water extraction may be performed by adding a small amount, for example, 10% by mass or less of an alcohol, preferably ethanol, to the water in order to increase the extraction efficiency and shorten the extraction time.
  • the extraction time in the case of water extraction is not particularly limited as long as it is a time during which the active ingredient is extracted, and can be appropriately set according to the temperature of extraction within a range of several seconds to several tens of hours.
  • Extraction with hot water can be carried out by a commonly used method as shown below, but it is not limited thereto. Extraction is carried out by heating Euglana after introducing it into a commonly used extractor together with water. In the case of extraction using boiling water or water in the supercritical state, it is necessary to use an extractor capable of withstanding the water vapor pressure.
  • the pressure at the time of extraction can be set to 1 to 5000 atm, preferably 60 to 400 atm. In the case of extraction under high temperature and pressure, if the extraction time is too long, the active ingredient may be decomposed or a chemical reaction may occur. Therefore, when extraction is performed under high temperature and high pressure, the extraction time is preferably short, for example, 3 minutes or less, more preferably 1 minute or less, and particularly preferably 30 seconds or less.
  • the extracted Euglena extract can be used as it is as an active ingredient of the muscle mass increasing agent according to the present embodiment, the extract can be further separated by an appropriate separation means (eg, distribution extraction, gel filtration method, silica gel chromatography It is also possible to fractionate the highly active fraction by chromatography, reverse phase or normal phase high performance liquid chromatography, etc.).
  • the Euglena extract or a fraction thereof may be concentrated and dried to remove an aqueous solvent, which may be used as an aqueous solvent extract.
  • the muscle mass increasing agent according to the present embodiment is a muscle mass increasing agent (muscle mass increasing agent) containing an Euglena-derived substance as an active ingredient.
  • the “Euglena-derived substance” includes Euglena algal cells such as Euglena live cells and dried algal cells of Euglena, as well as aqueous solvent extracts of Euglena, processed products of Euglena algal bodies, and the like.
  • muscle mass increaser refers to an agent that increases muscle mass (muscle mass) and is synonymous with “muscle mass increaser”.
  • the increase in muscle mass can be evaluated, for example, by measuring the muscle mass using a muscle mass meter or the like.
  • the muscle targeted for increase in muscle mass is not particularly limited, but skeletal muscle is preferred.
  • the skeletal muscle includes, for example, chest-crest mastoid muscle, pectoralis major muscle, minor pectoral muscle, anterior serratus muscle, subclavian muscle, rectus abdominis muscle, external oblique muscle, internal oblique muscle, transverse abdominal muscle, hippocampus muscle, Cap muscles, latissimus dorsi, erector spinae muscles, elevated shoulder muscles, rhomboids, deltoids, detrusors, supraspinatus, infraspinatus, subscapularis, great fornix, brachial muscles, biceps brachii , Brachial muscle, brachial muscle, triceps brachial muscle, elbow muscle, circular pronation muscle, square pronation muscle, pronation muscle, ulnar carpal flexor muscle, dorsal carpal flexor muscle, long palm muscle, superficial flexor muscle
  • the quadriceps muscles are involved in the extension of the knee joint and the flexion of the hip joint, specifically, the action of stretching and standing the knee, the walking action, and the running action. Therefore, when the muscle mass of the quadriceps femoris increases, movements such as standing up, walking and running improve, and locomotive syndrome and sarcopenia can be prevented and improved.
  • the euglena-derived substance can be used as a muscle enhancing agent since it has an action to increase muscle mass.
  • the "muscle-enhancing agent” refers to an agent that strengthens muscles, and muscle strengthening can be evaluated by, for example, muscle mass and muscle strength.
  • “Strengthening muscles” means increasing muscle mass and improving muscle strength. An increase in muscle mass is determined, for example, from measurement of muscle mass, and an improvement in muscle strength is determined, for example, from measurement of muscle strength by a muscle meter or the like.
  • the muscle mass increaser contains an Euglena-derived substance as an active ingredient, and is an agent for preventing locomotive syndrome for preventing or treating locomotive syndrome and sarcopenia, an agent for treating locomotive syndrome, an agent for preventing sarcopenia, and a treatment for sarcopenia Can also be used.
  • “To treat locomotive syndrome” and “to treat sarcopenia” refer to the symptoms of locomotive syndrome and sarcopenia compared to the condition before taking the euglena-derived substance which is the active ingredient of the muscle mass increasing agent of this embodiment. It means to reduce.
  • the muscle mass increaser according to the present embodiment contains an Euglena-derived substance as an active ingredient, and may be used also as a motor function maintenance agent for maintaining the motor function or a motor function improvement agent for improving the motor function. it can. “Maintaining the motor function” means “stand up” or “walk” as compared with the state to be compared, for example, the state before taking the euglena-derived substance which is the active ingredient of the muscle mass increasing agent of the present embodiment. It means that motor function such as is maintained.
  • “Improvement of motor function” means “stand up” or “walk” as compared with the condition to be compared, for example, the condition before taking the euglena-derived substance which is the active ingredient of the muscle mass increasing agent of the present embodiment. Say that motor function such as is improved.
  • the Euglena-derived substance has an action of suppressing the expression of a muscle atrophy-related gene, it can be used as a muscle atrophy-related gene expression inhibitor, a muscle atrophy preventive agent, and a muscle protein degradation inhibitor.
  • muscle atrophy-related genes whose expression is suppressed by euglena-derived substances include, for example, ubiquitin ligase genes (Cbl-b (SEQ ID NO: 1), Atrogin-1 (SEQ ID NO: 2), MuRF1 (SEQ ID NO: 3)) Is illustrated.
  • Muscle synthesis related gene expression promoter and muscle synthesis promoter Euglena-derived substances have the effect of promoting the expression of muscle synthesis-related genes, and thus can be used as muscle synthesis-related gene expression promoters and muscle synthesis promoters.
  • a muscle synthesis related gene whose expression is promoted by the euglena-derived substance, for example, the gene of S6K (SEQ ID NO: 5) which promotes the synthesis of muscle protein is exemplified.
  • the muscle mass increasing agent containing the Euglena-derived substance according to the embodiment as an active ingredient is administered to a patient with decreased muscle mass or muscle strength, or a patient who has a definitive diagnosis of locomotive syndrome or sarcopenia.
  • the muscle mass increasing agent containing the Euglena-derived substance of the present embodiment as an active ingredient is constituted as a food composition such as a pharmaceutical composition, a health food, etc. Prophylactically administered to people with locomotive syndrome or sarcopenia reserve forces, such as those who are likely to suffer from locomotive syndrome or sarcopenia.
  • Euglena-derived substances such as Euglena algae can be taken as food and have no side effects, so they can be administered even before a definitive diagnosis of locomotive syndrome or sarcopenia.
  • the muscle mass increasing food composition containing the Euglena-derived substance according to the present embodiment as an active ingredient, and the target for administering the muscle mass increasing agent are limited to persons having the above condition or condition or animals other than human beings Absent.
  • a muscle composition for increasing muscle mass and an agent for increasing muscle mass which contain an Euglena-derived substance as an active ingredient, can be administered to humans of 40 years of age or older, particularly to elderly people of 60 or 65 years of age. People over the age of 40, especially elderly people over the age of 60 or 65, tend to lose muscle mass and muscle strength with age, but with the Euglena-derived substance, the muscle mass increasing action Can reduce muscle mass loss and muscle strength loss.
  • the food composition for increasing muscle mass and muscle mass increasing agent of the present embodiment since muscle mass can be increased, prevention and treatment of diseases associated with decrease in muscle mass and muscle strength, bed rest state It is expected to be applied to the prevention of injuries and the prevention of injuries caused by falls.
  • the muscle mass increasing agent containing the Euglena-derived substance according to the present embodiment as an active ingredient may be added to a pharmacologically acceptable additive and used as a composition such as a food composition, a pharmaceutical composition, etc. it can.
  • the Euglena-derived substance of the present embodiment can also be used for food.
  • food compositions for preventing, muscle synthesis-related gene expression promotion, or muscle synthesis promotion use various amounts of food materials as an effective amount of an euglena-derived substance capable of effectively exerting the intended action. By blending, it is possible to provide a food composition having the effect.
  • the present invention can provide a food composition of food labeled as for increasing muscle mass and the like in the field of food.
  • the food composition include, in addition to general foods, food for specified health use, nutritive function food, functional display food, food for hospital patients, supplement and the like. It can also be used as a food additive.
  • Examples of the food composition include seasonings, processed meat products, processed agricultural products, beverages (soft drinks, alcoholic drinks, alcoholic drinks, carbonated drinks, milk drinks, fruit drinks, tea, coffee, nutritional drinks, etc.), powdered drinks (powders) Juices, powdered soups, etc., concentrated beverages, confectionery (candy (nodice), cookies, biscuits, gums, gummi, chocolate, etc.), bread, cereals, etc. can be mentioned. Further, in the case of food for specified health use, nutritive function food, functional display food and the like, it may be in the form of capsules, troches, syrups, granules, powders and the like.
  • the food for specified health use is a food containing a health functional ingredient that affects physiological functions etc., and can be displayed as being suitable for a specific use of health with the permission of the Commissioner of the Consumer Agency. is there.
  • the present invention as a specific health application, "helps to suppress the decrease in muscle mass and muscle strength necessary to live an independent daily life”, “helps to improve walking ability”, “maintenance of muscle mass and muscle strength”, “Support for maintenance of muscle mass and muscle strength”, “maintenance of walking ability that declines with age in middle-aged and elderly people”, “Supporting the ability to create muscles that help maintain muscles that decline with aging,” etc.
  • the nutritive function food is a food used for supplementation of nutritional components (vitamins, minerals), and displays the function of the nutritional components.
  • the amount of nutritional component contained in the daily intake standard amount is necessary for the amount of nutritional component contained in the daily intake standard amount to be within the defined upper limit value and lower limit value, and not only the display of nutritional function but also alert display etc.
  • the functional labeling food is a food which displays scientific basis-based functionality at the responsibility of the business operator. Information on the basis of safety and functionality etc. was sent to the Secretary General of the Consumer Agency before sales.
  • the food composition according to the present embodiment in addition to the Euglena-derived substance, it is possible to freely select and mix one or two or more kinds of components that can be used for the food composition.
  • all additives which can usually be used in the food field can be contained, such as various seasonings, preservatives, emulsifiers, stabilizers, flavors, coloring agents, preservatives, pH adjusters and the like.
  • HMB 3-hydroxy-3-methylbutyrate
  • the muscle mass increase agent of the present embodiment locomotive syndrome preventive agent, locomotive syndrome therapeutic agent, sarcopenia preventive agent, sarcopenia therapeutic agent, motor function maintenance agent, motor function improvement agent, muscle atrophy related gene expression inhibitor, muscle protein degradation inhibitor
  • a muscle atrophy preventive agent, a muscle synthesis related gene expression promoter and a muscle synthesis promoter are used together with a pharmaceutically acceptable carrier or additive together with an amount of an euglena-derived substance capable of effectively exerting the intended action.
  • a pharmaceutical composition having the above-mentioned action is provided.
  • the pharmaceutical composition may be a pharmaceutical or quasi-drug.
  • the pharmaceutical composition may be applied internally or externally.
  • the pharmaceutical composition is used in the form of an internal preparation, intravenous injection, subcutaneous injection, intradermal injection, injection such as intramuscular injection and / or intraperitoneal injection, transmucosal application, transdermal application and the like.
  • the dosage form of the pharmaceutical composition can be appropriately set depending on the form of application, for example, solid preparations such as tablets, granules, capsules, powders, powders, etc., liquid preparations such as solutions, suspensions, etc.
  • Semisolid agents such as ointments or gels are included.
  • one or more pharmaceutically acceptable additives can be freely selected and contained.
  • excipients for example, excipients, binders, disintegrants, surfactants, preservatives, coloring agents, flavoring agents, fragrances, stabilizers, preservatives
  • DDS drug delivery system
  • HMB 3-hydroxy-3-methylbutyrate
  • the muscle mass increasing agent of the present embodiment may be orally administered by a powder, capsule, tablet, granule, solution, syrup or the like.
  • the dose and administration form of the muscle mass increasing agent of the present embodiment may be appropriately selected depending on the subject, the pathological condition, the progress of the condition, and other conditions.
  • Euglena when Euglena is selected as an Euglena-derived substance and orally administered for the purpose of obtaining a muscle mass increasing effect for human (adult), Euglena is generally 1 to 5000 mg by dry weight per day, preferably It is recommended to administer continuously once or twice a day (morning and evening), and at a rate of 5 times a week or more, so as to be about 100 to 3000 mg, more preferably about 500 to 2000 mg.
  • Euglena powder was used as an Euglena-derived substance, and the influence of continuous intake of Euglena powder on muscle mass and muscle-related genes was examined.
  • Example 1 As a muscle mass increasing agent, Euglena gracilis powder (Euglena algal, manufactured by Euglena Co., Ltd.) which is a substance derived from Euglena was used.
  • Study 1 aims to clarify the effect of euglena intake on muscle mass in mice that are not disease models.
  • the quadriceps femoris muscle and liver after intake for 4 weeks were used as samples.
  • the control group was fed with CE-2 (normal diet), and the Euglena group was fed with CE-2 (Euglena diet) containing 2% Euglena (Table 4).
  • CE-2 normal diet
  • CE-2 Euglena diet
  • Table 4 After a 4-week feeding period, quadriceps muscles and liver were collected from the mice and organ weights were measured.
  • the quadriceps muscles are involved in the extension of the knee joint and the flexion of the hip joint, specifically, the action of stretching and standing the knee, the walking action, and the running action.
  • Euglena as an euglena-derived substance has an action of increasing the muscle mass of the quadriceps femoris muscle, and can improve movements such as standing up, walking, running and the like, thereby preventing and / or locomotive syndrome and sarcopenia. It has been found that it can be used to improve.
  • mice Male, 12 weeks old, 32 animals are divided into groups so that the average body weight is equal, and the normal rearing group (-), tail suspension group (C), tail suspension + Euglena low concentration group (EL) Tail suspension + Euglena high concentration group (EH).
  • Water is used for the normal rearing group and tail suspension group, and the euglena is 40 mg / mouse or 80 mg / mouse for tail suspension + low Euglena concentration (EL) and tail suspension + high euglena concentration (EH), respectively. It was orally administered once a day.
  • the tail suspension test was started 7 days after the start of administration, and 10 days after the start of the tail suspension test, it was sacrificed under isoflurane anesthesia.
  • RNA was extracted by abdominal aortic blood collection, and each muscle of liver, soleus muscle, plantar muscle, gastrocnemius muscle, and quadriceps femoris muscle was removed and weighed. After extracting RNA from the plantar and quadriceps muscles with Tri reagent, cDNA is synthesized, and each gene (Cbl-b (SEQ ID No. 1), Atrogin-1 (SEQ ID No. 2), MuRF1 (SEQ ID No.) is synthesized by real-time PCR. 3) The expression levels of 4E-BP1 (SEQ ID NO: 4) and RPS6KB1 (SEQ ID NO: 5) were measured. ⁇ -actin was used as an internal standard.
  • FIGS. The results of muscle weight measurements are shown in FIGS. As shown in FIG. 6, a decrease in muscle weight was observed in the tail suspension compared to the normal rearing group, and it was confirmed that the tail suspension induced disuse muscle atrophy. As shown in FIG. 7, in the plantar and quadriceps muscles, Euglena consumption inhibited the decrease in muscle weight. Euglena contains many components, which may have contributed to the inhibition of muscle protein degradation or the promotion of synthesis.
  • Euglena can be used to suppress the decrease in muscle weight of the plantar and quadriceps muscles.
  • Euglena can be used as a therapeutic agent or prophylactic agent for locomotive syndrome or sarcopenia, because reduction of muscle mass of plantar muscles and quadriceps leads to development of locomotive syndrome and sarcopenia.
  • the plantar muscles and quadriceps muscles are muscles that are strongly associated with motor function, it is possible to use Euglena as a motor function maintenance agent or a motor function improvement agent.
  • Euglena was selected from the ubiquitin ligase genes (Cbl-b (SEQ ID NO: 1), Atrogin-1 (SEQ ID NO: 2), MuRF1 (SEQ ID NO: 3)) involved in the degradation of muscle proteins. It has been found that it can be used as a muscle atrophy-related gene expression inhibitor for suppressing the expression of In addition, it was found that Euglena can be used as a muscle protein degradation inhibitor that inhibits the degradation of muscle protein and a muscle atrophy preventive agent that prevents muscle atrophy.
  • Cbl-b SEQ ID NO: 1
  • Atrogin-1 SEQ ID NO: 2
  • MuRF1 SEQ ID NO: 3
  • Euglena can be used as a muscle synthesis related gene expression promoter that promotes the expression of muscle synthesis related genes. Moreover, it turned out that it is possible to use Euglena as a muscle synthesis promoter which promotes muscle synthesis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition alimentaire pour augmenter la masse musculaire, un agent d'augmentation de masse musculaire, un agent thérapeutique pour le syndrome de la locomotion, un agent thérapeutique pour la sarcopénie, un agent d'entretien de fonction d'exercice, un inhibiteur d'expression génique liée à une atrophie musculaire, un inhibiteur de dégradation de protéine musculaire, un agent de prévention d'atrophie musculaire, un promoteur d'expression génique liée à la synthèse musculaire et un promoteur de synthèse musculaire. L'invention concerne une composition alimentaire pour augmenter la masse musculaire, un agent d'augmentation de masse musculaire, un agent thérapeutique pour le syndrome de la locomotion, un agent thérapeutique pour la sarcopénie, un agent d'entretien de fonction d'exercice, un inhibiteur d'expression génique liée à une atrophie musculaire, un inhibiteur de dégradation de protéine musculaire, un agent de prévention d'atrophie musculaire, un promoteur d'expression génique liée à la synthèse musculaire et un promoteur de synthèse musculaire, caractérisée par le fait qu'elle contient une substance dérivée d'Euglena comme principe actif.
PCT/JP2018/028756 2017-08-01 2018-07-31 Composition alimentaire pour augmenter la masse musculaire, agent d'augmentation de masse musculaire, agent thérapeutique pour le syndrome de la locomotion, agent thérapeutique pour la sarcopénie, agent d'entretien de fonction d'exercice, inhibiteur d'expression génique liée à une atrophie musculaire, inhibiteur de dégradation de protéine musculaire, agent de prévention d'atrophie musculaire, promoteur d'expression génique liée à la synthèse musculaire, et promoteur de synthèse musculaire Ceased WO2019026930A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201880049823.XA CN111031812A (zh) 2017-08-01 2018-07-31 用于增加肌肉量的食品组合物、肌肉量增加剂、运动障碍综合征治疗剂、少肌症治疗剂、运动功能维持剂、肌萎缩相关基因表达抑制剂、肌肉蛋白质分解抑制剂、肌萎缩预防剂、肌肉合成相关基因表达促进剂及肌肉合成促进剂

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2017-149413 2017-08-01
JP2017149413 2017-08-01
JP2017254319A JP6524204B2 (ja) 2017-08-01 2017-12-28 筋量増加用食品組成物、筋量増加剤、筋萎縮予防用の食品組成物及び筋萎縮予防剤
JP2017-254319 2017-12-28

Publications (1)

Publication Number Publication Date
WO2019026930A1 true WO2019026930A1 (fr) 2019-02-07

Family

ID=65232841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/028756 Ceased WO2019026930A1 (fr) 2017-08-01 2018-07-31 Composition alimentaire pour augmenter la masse musculaire, agent d'augmentation de masse musculaire, agent thérapeutique pour le syndrome de la locomotion, agent thérapeutique pour la sarcopénie, agent d'entretien de fonction d'exercice, inhibiteur d'expression génique liée à une atrophie musculaire, inhibiteur de dégradation de protéine musculaire, agent de prévention d'atrophie musculaire, promoteur d'expression génique liée à la synthèse musculaire, et promoteur de synthèse musculaire

Country Status (1)

Country Link
WO (1) WO2019026930A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3989730A4 (fr) * 2019-06-28 2023-09-06 Noblegen Inc. Procédés d'extraction de protéines et de traitement en aval d'euglènes
EP4209579A4 (fr) * 2020-09-02 2025-01-08 Nissin Foods Holdings Co., Ltd. Bifidobactérie inhibant l'expression d'un gène de l'atrophie musculaire

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0870848A (ja) * 1994-09-02 1996-03-19 Nakano Vinegar Co Ltd ビタミンＥおよびβ−カロチン高含有量のユーグレナ藻体およびその製造方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0870848A (ja) * 1994-09-02 1996-03-19 Nakano Vinegar Co Ltd ビタミンＥおよびβ−カロチン高含有量のユーグレナ藻体およびその製造方法

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
HICHIDA, MANA ET AL.: "Suppression action of disuse muscle atrophy by measns of intake of euglena", LECTURE ABSTRACTS OF THE 72TH CONFERENCE OF JAPAN SOCIETY OF NUTRITION AND FOOD SCIENCE, 27 April 2018 (2018-04-27), pages 220 *
KUSMIC, C. ET AL.: "Euglena gracilis as source of the antioxidant vitamin E. Effects of culture conditions in the wild strain and in the natural mutant WZSL", JOURNAL OF APPLIED PHYCOLOGY, vol. 10, no. 6, 1 December 1999 (1999-12-01), pages 555 - 559, XP055572966, ISSN: 1573-5176 *
MOKROSNOP, V. M. ET AL.: "Accumulation of alpha- tocopherol and beta-carotene in Euglena gracilis Cells Under Autotrophic and Mixotrophic Culture Conditions", APPLIED BIOCHEMISTRY AND MICROBIOLOGY, vol. 52, no. 2, 31 March 2016 (2016-03-31), pages 216 - 221, XP035655823, ISSN: 0003-6838 *
NAKASHIMA, YUYA ET AL.: "Preventive effects of Chlorella on skeletal muscle atrophy in muscle- specific mitochondrial aldehyde dehydrogenase 2 activity-deficient mice", BMC COMPLEMENT. ALTERN. MED., vol. 14, no. 1, 11 October 2014 (2014-10-11), pages 390, XP021201020, ISSN: 1472-6882 *
OGAWA, MASAHIRO ET AL.: "beta-carotene suppresses disuse muscle atrophy caused by sciatic neurectomy", VITAMINS, vol. 86, no. 4, 2012, pages 287, XP055573024, ISSN: 0006-386X *
OGAWA, MASAHIRO ET AL.: "The preventive effect of beta-carotene on denervation-induced soleus muscle atrophy in mice", BR. J. NUTR., vol. 109, no. 08, April 2013 (2013-04-01), pages 1349 - 1358, XP055572972, ISSN: 0007-1145 *
TAKEYAMA, HARUKO ET AL.: "Production of antioxidant vitamins, beta-carotene, vitamin C, and vitamin E, by two-step culture of Euglena gracilis Z", BIOTECHNOL. BIOENG., vol. 53, no. 2, 20 January 1997 (1997-01-20), pages 185 - 190, XP055572965, ISSN: 1097-0290 *
TAKIZAWA, AKIKO ET AL.: "Effects of vitamin C deficiency on skeletal muscle", VITAMINS, vol. 91, no. 4, 25 April 2017 (2017-04-25), pages 270, ISSN: 0006-386X *
UMEI, NAMIKO ET AL.: "Preventive Effects of Antioxidants on Muscle Atrophy Induced by Ischemic Reperfusion", J. PHYS. THER. SCI., vol. 23, no. 4, 2011, pages 565 - 567, XP055573055, ISSN: 2187-5626 *
WATANABE, FUMIO ET AL.: "Biochemistry and Physiology of Vitamins in Euglena", ADV. EXP. MED. BIOL., vol. 979, 21 April 2017 (2017-04-21), pages 65 - 90, ISSN: 0065-2598 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3989730A4 (fr) * 2019-06-28 2023-09-06 Noblegen Inc. Procédés d'extraction de protéines et de traitement en aval d'euglènes
EP4209579A4 (fr) * 2020-09-02 2025-01-08 Nissin Foods Holdings Co., Ltd. Bifidobactérie inhibant l'expression d'un gène de l'atrophie musculaire

Similar Documents

Publication Publication Date Title
Tarazona-Díaz et al. Watermelon juice: potential functional drink for sore muscle relief in athletes
TWI830696B (zh) 抑制肌纖維變性用組成物
EP2081582A1 (fr) Extraits de romarin, compositions pharmaceutiques et diététiques les contenant et leurs utilisations
JP6524204B2 (ja) 筋量増加用食品組成物、筋量増加剤、筋萎縮予防用の食品組成物及び筋萎縮予防剤
WO2019026930A1 (fr) Composition alimentaire pour augmenter la masse musculaire, agent d'augmentation de masse musculaire, agent thérapeutique pour le syndrome de la locomotion, agent thérapeutique pour la sarcopénie, agent d'entretien de fonction d'exercice, inhibiteur d'expression génique liée à une atrophie musculaire, inhibiteur de dégradation de protéine musculaire, agent de prévention d'atrophie musculaire, promoteur d'expression génique liée à la synthèse musculaire, et promoteur de synthèse musculaire
JP6782381B1 (ja) 脳機能改善用食品組成物、脳機能改善剤、脳由来神経栄養因子増加用食品組成物、ストレスホルモン分泌抑制用食品組成物、脳由来神経栄養因子増加剤及びストレスホルモン分泌抑制剤
WO2019146735A1 (fr) Composition pour prévention ou amélioration de la douleur nociceptive
CN101336709A (zh) 一种抗疲劳营养制剂
CN104349786B (zh) 骨骼肌慢肌化剂
CN101633945A (zh) 一种含vvyp肽的珠肽粉的制备方法
KR20160070912A (ko) 진피 추출물을 포함하는 이상 체중 감소 증상의 예방 또는 치료용 조성물
Kazemi et al. Evaluation the effect of royal jelly on the growth of two members of gut microbiota; Bacteroides fragillis and Bacteroides thetaiotaomicron.
JP7286335B2 (ja) 骨密度改善用食品組成物、骨密度改善剤、前駆骨芽細胞増殖用食品組成物、骨分化促進用食品組成物、骨強化用食品組成物、抗骨粗鬆症用食品組成物、前駆骨芽細胞増殖剤、骨分化促進剤、骨強化剤、抗骨粗鬆症剤、骨密度改善剤の製造方法、前駆骨芽細胞増殖剤の製造方法、骨分化促進剤の製造方法、骨強化剤の製造方法及び抗骨粗鬆症剤の製造方法
WO2007128465A1 (fr) Nouvelle utilisation de composés organiques
CN110740741A (zh) 马齿苋加工品、马齿苋加工品的制造方法、补充剂、医药品、肠管黏膜保护剂以及整肠剂
CN110325195A (zh) 脂肪细胞分化抑制剂、用于抑制脂肪细胞分化的食品组合物及脂肪细胞分化抑制剂的制造方法
CN107837298A (zh) 一种沙棘油保健品
WO2016206363A1 (fr) Utilisation d'oligopeptide de ginseng de jilin dans la préparation d'un produit alimentaire anti-oxydant ou d'un produit alimentaire de soins de santé
JP7162542B2 (ja) 食品因子センシング関連遺伝子発現促進用食品組成物及び食品因子センシング関連遺伝子発現促進剤
WO2015190682A1 (fr) Composition pour la promotion de la croissance contenant de l'acide coumarique comme principe actif
JP2017197491A (ja) 筋肉増強用組成物
Ballinger Razalean Review: Is It Safe and Effective for Weight Loss?
JP2018100237A (ja) 運動機能低下予防又は改善用組成物
CN101143203A (zh) 一种具有护肝养胃功能的复方口服液
CN116648145A (zh) 肌肉柔软性改善用组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18840172

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18840172

Country of ref document: EP

Kind code of ref document: A1